Home › SEC Filings › Insider Cluster Activity
Insider Cluster Activity
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| BCRX | CLUSTER | neutral | 4/10 | Director Theresa Heggie sold 49,933 shares of BioCryst Pharmaceuticals for $504,823 in an open-market transaction. This | Mar 24, 2026 |
| UTHR | CLUSTER | neutral | 4/10 | United Therapeutics CEO Martine Rothblatt and other insiders engaged in a series of derivative exercises and open-market | Mar 23, 2026 |
| ALXO | CLUSTER | neutral | 3/10 | Two corporate insiders at ALX Oncology sold shares in a coordinated open-market transaction on March 19, 2026, including | Mar 23, 2026 |
| HBIO | CLUSTER | neutral | 3/10 | HBIO CEO received a non-cash grant of 75,000 shares, while a director made an open-market purchase of 10,000 shares for | Mar 23, 2026 |
| IBIO | CLUSTER | bullish | 5/10 | Two insiders at iBio, Inc. (IBIO) purchased shares in the open market on March 19, 2026, including CFO Felipe Duran who | Mar 23, 2026 |
| EOLS | CLUSTER | bearish | 6/10 | Two Evolus insiders, David Moatazedi and Rui Avelar, conducted a series of open-market share sales totaling $797,936 ove | Mar 20, 2026 |
| BCAX | CLUSTER | neutral | 3/10 | CEO Claire Mazumdar and President Ryan Cohlhepp of Bicara Therapeutics (BCAX) exercised stock options and sold shares in | Mar 20, 2026 |
| UTHR | CLUSTER | neutral | 4/10 | United Therapeutics CEO Martine Rothblatt and other insiders engaged in a series of derivative exercises and open-market | Mar 20, 2026 |
| ALDX | CLUSTER | bullish | 5/10 | Two corporate insiders at Aldeyra Therapeutics purchased shares in the open market within a 7-day window, totaling $105, | Mar 20, 2026 |
| UTHR | CLUSTER | neutral | 4/10 | Multiple United Therapeutics insiders, including CEO Martine Rothblatt and CFO James Edgemond, engaged in significant st | Mar 19, 2026 |
| BBIO | CLUSTER | neutral | 3/10 | BridgeBio Pharma CEO Kumar Neil was granted a total of 144,883 shares in non-cash awards and sold 9,690 shares in an ope | Mar 19, 2026 |
| CSTL | CLUSTER | bearish | 6/10 | Castle Biosciences CEO Derek Maetzold sold 49,953 shares in the past week through open-market transactions, totaling app | Mar 19, 2026 |
| ZLAB | CLUSTER | bearish | 5/10 | A cluster of insider transactions at Zai Lab Ltd (ZLAB) over the past week shows one director buying $32.7K in shares wh | Mar 19, 2026 |
| EOLS | CLUSTER | bearish | 7/10 | Two Evolus insiders, including CEO David Moatazedi and executive Rui Avelar, sold shares in the open market, totaling $7 | Mar 18, 2026 |
| CRNX | CLUSTER | bearish | 6/10 | Two corporate insiders at Crinetics Pharmaceuticals sold shares in the past week, including CEO Richard Scott Struthers | Mar 18, 2026 |
| UTHR | CLUSTER | neutral | 5/10 | United Therapeutics insiders executed a cluster of transactions over the past week, led by CEO Martine Rothblatt and oth | Mar 18, 2026 |
| ESPR | CLUSTER | neutral | 4/10 | Multiple executives at Esperion Therapeutics, including the CEO, CFO, and Chief Legal Officer, sold shares in the open m | Mar 18, 2026 |
| IRD | CLUSTER | neutral | 3/10 | Two Opus Genetics executives, including the CEO and Chief Scientific & Development Officer, sold shares in the past week | Mar 18, 2026 |
| ALLO | CLUSTER | neutral | 3/10 | Two senior executives at Allogene Therapeutics, including the CEO and Chief Technical Officer, sold shares in a coordina | Mar 18, 2026 |
| HBIO | CLUSTER | bullish | 6/10 | Two corporate insiders at Harvard Bioscience purchased shares in the open market within the past week, including CEO Joh | Mar 18, 2026 |
| CYRX | CLUSTER | neutral | 4/10 | Three key executives at Cryoport, the CEO, CFO, and Chief Scientific Officer, sold shares in the past week, with total o | Mar 17, 2026 |
| STOK | CLUSTER | neutral | 2/10 | A single insider sale occurred at Stoke Therapeutics, with Director Arthur A. Levin selling 605 shares for $22,264 in th | Mar 17, 2026 |
| DNTH | CLUSTER | bearish | 7/10 | Dianthus Therapeutics CEO, R&D head, and CFO-equivalent executed a coordinated cluster of derivative exercises and open- | Mar 17, 2026 |
| NATR | CLUSTER | neutral | 4/10 | Seven executives at Nature's Sunshine Products sold shares in a concentrated 7-day window, including two open-market sal | Mar 17, 2026 |
| UPB | CLUSTER | neutral | 3/10 | Three corporate insiders at Upstream Bio, Inc. (UPB) sold shares in a coordinated open-market transaction on March 16, 2 | Mar 17, 2026 |
| UTHR | CLUSTER | bearish | 6/10 | United Therapeutics CEO Martine Rothblatt conducted a series of derivative exercises and open-market sales over the past | Mar 17, 2026 |
| CSTL | CLUSTER | bearish | 7/10 | CEO Derek Maetzold and Chief Commercial Officer Juvenal Tobin sold a combined $2.4M in open-market transactions over fiv | Mar 17, 2026 |
| LQDA | CLUSTER | bearish | 7/10 | Multiple insiders at Liquidia Corp sold shares in the past week, including C-suite executives selling over $1.9 million | Mar 17, 2026 |
| ORKA | CLUSTER | bearish | 5/10 | Multiple Oruka Therapeutics executives, including the CEO, CMO, and COO, sold shares in a coordinated cluster over a sin | Mar 17, 2026 |
| VRTX | CLUSTER | neutral | 3/10 | Two Vertex Pharmaceuticals EVPs, the Chief Medical Officer and Chief Commercial Officer, sold shares in open-market tran | Mar 17, 2026 |